a collection of information unless it contains a valid OMB control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10727320			
Filing Date		2003-12-03			
First Named Inventor	Lefur	Lefurgy			
Art Unit		2116			
Examiner Name	Sugent, James				
Attorney Docket Number		AU920030894US1			

	Remove					
		Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	
	1	5148546		1992-09-15	Blodgett	
	2	5404543		1995-04-04	Faucher, et al.	
	3	6330639	B1	2001-12-11	Fanning, et al.	
	4	6657634		2003-12-02	Sinclair, et al.	
	5	5623647		1997-04-22	Maitra, et al.	
	6	6776787	B2	2004-06-10	Green	
	7	6996441	B1	2006-02-07	Tobias	
f you wish	1 to ac	ı dd additional U.S. Pat	ent citatio	n information p	lease click the Add button.	Add

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10727320		
Filing Date		2003-12-03		
First Named Inventor	Lefurgy			
Art Unit		2116		
Examiner Name	Suge	nt, James		
Attorney Docket Number		ALIG20030804LIS1		

Examiner Initial*	Cite No	Publi	cation Number	Kind Code <sup>1</sup>	Publica Date	ition	Name of Pate of cited Docu			Releva		s,Lines wher ages or Rele	
	1	2003	0210247	A1	2003-1	1-13	Cui, et al.						
	2	2004	0044914	A1	2004-0	4-03-04 Gedeon							
	3	2004	0083478	A1	2004-0	4-29	Chen, et al.						
If you wis	h to a	dd add	itional U.S. Publi	shed Ap	plication	citatio	n information p	oleas	e click the Ad	d buttor	Add		
					FOREIG	3N PA1	ENT DOCUM	ENT:	s		Remov	Э	
Examiner Initial*	Cite No	Forei	gn Document ber <sup>3</sup>	Country Code <sup>2</sup>		Kind Publication Code <sup>4</sup> Name of Patentee or Applicant of cited Document Passages or Figures Appe		elevant s or Relevan	т				
	1												
If you wisl	h to a	dd add	itional Foreign P	atent Do	cument	citation	information pl	lease	click the Add	button	Add		
				NON	I-PATE	NT LITE	RATURE DO	CUM	ENTS		Remov	0	
Examiner Initials*	Examinor Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, ctyl and/or country when published.						T5						
	1												
If you wis	h to a	dd add	itional non-paten	t literatu	re docu	ment cit	ation informati	ion pl	lease click the	Add b	utton A	dd	
							R SIGNATUR						_
Examiner	Signa	ture							Date Conside	ered			_
*EXAMIN	ER: Ir	nitial if i	reference conside	ered. wh	ether or	not cit:	ation is in confi	orma	nce with MPE	P 609.	Draw lin	e through a	_

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Application Number		10727320	
INFORMATION DIGGI COURT	Filing Date		2003-12-03	
INFORMATION DISCLOSURE	First Named Inventor Lefur		gy	
(Not for submission under 37 CFR 1.99)	Art Unit		2116	
(Notice submission under or or it issue	Examiner Name Suge		ent, James	
	Attorney Docket Numb	er	AU920030894US1	

See four Codes of USPTO Patient Documents at your USPTO, CODE on MEPP 901.04. \* Exister office in all assets for electrons, by the loss letter code (WPO) Standard 51.3. \* \*Projectioned projection pr

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10727320		
Filing Date		2003-12-03		
First Named Inventor	Lefurgy			
Art Unit		2116		
Examiner Name	Sugent, James			
Attorney Docket Number		AU920030894US1		

#### CERTIFICATION STATEMENT

1 10030 300 01	Of It 1.07 und	1.00 to make are a	ppropriate selections	(4).	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

#### ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a deepin patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Diagon one 37 CER 1 07 and 1 98 to make the appropriate colortion(c)

□ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mitch Harris#42,638/	Date (YYYY-MM-DD)	2006-06-08
Name/Print	Andrew Mitchell Hamis	Registration Number	42638

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 3T CFR. 11.4 This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.